FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock
This article was originally published in The Pink Sheet Daily
Executive Summary
Policy shifts to address opioid abuse epidemic include changes to immediate-release opioid labeling, updated REMS requirements, and a new advisory committee.
You may also be interested in...
A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: